Physician profile
Patrick Michael Differding
NPI 1356871016
$999.92
in general payments reported to CMS, 2019-2025
13 companies · $544 in 2025
The $544 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $131 · 2023: $93.33 · 2024: $232 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $345.87 | 2022-2025 | Rocklatan, Argos, Clareon Panoptix Pro |
| Abbvie INC. | $176.28 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $114.18 | 2022 | |
| Dompe US, INC. | $98.79 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $43.53 | 2023-2024 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $41.74 | 2024-2025 | Tecnis Simplicity, Catalys System |
| New World Medical,INC. | $39.85 | 2022-2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Harrow Eye, LLC | $38.01 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $24.52 | 2023 | Vyzulta |
| Tarsus Pharmaceuticals, INC. | $22.66 | 2025 | Xdemvy |
| Rxsight INC | $20.66 | 2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Horizon Therapeutics Plc | $20.10 | 2023 | Tepezza |
| Amgen INC. | $13.73 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Differding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.